ASNS

Across TCGA pan-cancer cohorts, ASNS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASNS data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ASNS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ASNS expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where ASNS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.448	0.916	.015	21	view →
LUAD	OS	Quartile	II,III,IV	0.448	0.823	.025	8	view →
HNSC	OS	Median	All	0.786	0.916	.005	7	view →
PDAC	OS	Quartile	All	0.444	0.632	.029	2	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.525	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASNS–CCRCC (OS)

Open the CCRCC breakdown →